sumatriptan has been researched along with Fatigue in 5 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effectiveness of a 5-HT(1B/1D) receptor agonist, sumatriptan, on a paroxysmal pain in trigeminal neuralgia." | 9.12 | Subcutaneous sumatriptan for refractory trigeminal neuralgia. ( Hoka, S; Kanai, A; Saito, M, 2006) |
| "To examine the effectiveness of a 5-HT(1B/1D) receptor agonist, sumatriptan, on a paroxysmal pain in trigeminal neuralgia." | 5.12 | Subcutaneous sumatriptan for refractory trigeminal neuralgia. ( Hoka, S; Kanai, A; Saito, M, 2006) |
| "The pathogenesis of migraine involves multiple peripheral and central neural mechanisms that individually have been successful targets for acute (abortive) and preventive treatment." | 2.71 | Sumatriptan and naproxen sodium for the acute treatment of migraine. ( Alexander, WJ; Littlefield, DE; Smith, TR; Spruill, SE; Stark, SR; Sunshine, A, 2005) |
| "Frovatriptan treatment produced an adverse events profile similar to that of placebo, and in a direct comparison study was better tolerated than sumatriptan 100 mg." | 2.70 | Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. ( Géraud, G; Keywood, C; Spierings, EL, 2002) |
| "Sumatriptan is a selective 5-HT(1B/D) receptor agonist which does not cross the blood-brain barrier." | 2.69 | Sumatriptan reduces exercise capacity in healthy males: a peripheral effect of 5-hydroxytryptamine agonism? ( Cahill, H; Hillis, WS; Hills, WS; Knipe, S; MacIntyre, PD; McCann, GP; Muir, DF, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Landy, S | 1 |
| Savani, N | 1 |
| Shackelford, S | 1 |
| Loftus, J | 1 |
| Jones, M | 1 |
| Smith, TR | 1 |
| Sunshine, A | 1 |
| Stark, SR | 1 |
| Littlefield, DE | 1 |
| Spruill, SE | 1 |
| Alexander, WJ | 1 |
| Kanai, A | 1 |
| Saito, M | 1 |
| Hoka, S | 1 |
| McCann, GP | 1 |
| Cahill, H | 1 |
| Knipe, S | 1 |
| Muir, DF | 1 |
| MacIntyre, PD | 1 |
| Hillis, WS | 1 |
| Hills, WS | 1 |
| Géraud, G | 1 |
| Spierings, EL | 1 |
| Keywood, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "An Open-label Study to Evaluate Completeness of Response Following Treatment With Treximet™ for Migraine"[NCT00893737] | Phase 4 | 147 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CORS scores for Pain (0-4), Associated Symptoms (0-4), Limbic/Affective Symptoms (0-5), and Speed of Return to Functionality (1-5), represent outcome measures that are relevant to patients. Higher scores represent better treatment efficacy.~The analysis compares CORS scores for usual triptan (pre-study) versus (vs.) Treximet (study medication)." (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Pain Score | Associated Symptoms Score | Limbic Symptoms Score | Functionality Score | |
| Treximet | 0.17 | 0.07 | 0.03 | 0.10 |
Scores calculated for (1) Efficacy (2) Functionality (3) Ease of use (4) Cost. Higher score represents better treatment satisfaction. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Efficacy | Functionality | Ease of Use | Cost | |
| Treximet | 8.61 | 13.86 | 2.76 | 7.28 |
CORS completed at Visit 1 regarding participant pre-study triptan and at Visit 2 regarding Treximet taken in study. Areas of therapeutic advantage evaluated: How often does 1 dose completely relieve (1) headache pain (2) neck/shoulder pain (3) nausea (4) light sensitivity (5) sound sensitivity (6) irritability. How quickly can/do you (1) concentrate or think clearly (2) resume normal activities (3) function normally (4) feel completely normal. How confident are you that (1) one dose will completely relieve migraine within 2 hours (2) once relieved, migraine will not return within 24 hours. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Percent of Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| How often 1 dose relieves headache pain | How often 1 dose relieves neck/shoulder pain | How often 1 dose relieves nausea | How often 1 dose relieves light sensitivity | How often 1 dose relieves sound sensitivity | How often 1 dose relieves irritability | How quickly can you concentrate or think clearly | How quickly can you resume normal activities | How quickly can you function normally | How quickly do you feel completely normal | Confidence 1 dose will relieve migraine in 2 hours | Confidence migraine will not return in 24 hours | |
| Treximet | 42 | 52 | 43 | 42 | 45 | 36 | 31 | 32 | 32 | 36 | 33 | 38 |
5 trials available for sumatriptan and Fatigue
| Article | Year |
|---|---|
Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine.
Topics: Adolescent; Adult; Aged; Dizziness; Double-Blind Method; Fatigue; Female; Humans; Menstrual Cycle; M | 2004 |
Sumatriptan and naproxen sodium for the acute treatment of migraine.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Synergism; | 2005 |
Subcutaneous sumatriptan for refractory trigeminal neuralgia.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Fatigue; Female; Humans; Injections, Subcutaneou | 2006 |
Sumatriptan reduces exercise capacity in healthy males: a peripheral effect of 5-hydroxytryptamine agonism?
Topics: Adult; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fatigue; Hemodynamics; Humans; M | 2000 |
Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Topics: Acute Disease; Adult; Carbazoles; Clinical Trials as Topic; Dizziness; Dose-Response Relationship, D | 2002 |